Hematology Practice Questions

Q: Autoimmune hemolytic anemia is seen in which of the following conditions?

Chronic lymphocytic leukemia (CLL). The correct answer is Chronic Lymphocytic Leukemia (CLL) because it is the most common leukemia associated with autoimmune phenomena [3]. In CLL, the neoplastic B-cells are dysfunctional; they act as antigen-presenting cells that can trigger T-cell imbalance. This leads to the production of polyclonal autoantibodies by non-neoplastic B-cells against self-antigens on red blood cells [2]. * **Warm Autoimmune Hemolytic Anemia (W-AIHA):** This occurs in approximately 5–10% of CLL patients. It is typically mediated by IgG antibodies [3]. * **Evans Syndrome:** CLL can also present with a combination of AIHA and Immune Thrombocytopenic Purpura (ITP). **Why other options are incorrect:** * **CML:** This is a myeloproliferative neoplasm characterized by the Philadelphia chromosome [1]. It typically presents with massive splenomegaly and a high white cell count, but autoimmune cytopenias are extremely rare. * **AML & ALL:** These are acute leukemias characterized by a "maturation arrest" and bone marrow failure. Anemia in these conditions is usually due to marrow infiltration (myelophthisis) or chemotherapy, rather than an autoimmune process. **High-Yield Clinical Pearls for NEET-PG:** * **Direct Antiglobulin Test (Coombs Test):** This is the gold standard for diagnosing AIHA in CLL patients [3]. * **Richter Transformation:** If a CLL patient with AIHA suddenly develops rapid lymphadenopathy and systemic symptoms, suspect transformation into Diffuse Large B-Cell Lymphoma (DLBCL). * **Treatment:** While the primary treatment for CLL is targeted therapy (like Ibrutinib), AIHA within CLL is initially managed with **corticosteroids**.

Q: A patient has just been admitted to the hospital for observation. Based on the patient's laboratory results, what is the patient's primary problem? Hematocrit 45%, Hemoglobin 16 g/dL, Platelets 50 x 10^9/L.

Recurrent nosebleeds. **Explanation:** The laboratory results provided show a **normal Hematocrit (45%)** and **normal Hemoglobin (16 g/dL)**, but a significantly **low Platelet count (50 x 10⁹/L)**. This condition is known as **thrombocytopenia** [1]. 1. **Why "Recurrent nosebleeds" is correct:** Platelets are essential for primary hemostasis. When the platelet count drops below the normal range (150–450 x 10⁹/L), the patient becomes prone to mucosal bleeding [2]. Epistaxis (nosebleeds), petechiae, and gum bleeding are classic clinical manifestations of thrombocytopenia [2],[3]. A count of 50 x 10⁹/L is low enough to increase the risk of bleeding from minor trauma or spontaneously [1]. 2. **Why the other options are incorrect:** * **Hemochromatosis:** This is a disorder of iron overload. While it may lead to high hemoglobin in some contexts or cirrhosis in late stages, it is not primarily defined by isolated thrombocytopenia. * **Deep Vein Thrombosis (DVT) & Hepatic Vein Thrombosis (Budd-Chiari):** These are thrombotic (clotting) disorders. While conditions like Heparin-Induced Thrombocytopenia (HIT) or PNH can involve both clots and low platelets, isolated thrombocytopenia in a stable patient is statistically and clinically more likely to present with bleeding (like epistaxis) rather than a major venous thrombosis unless other risk factors are present. **High-Yield Clinical Pearls for NEET-PG:** * **Normal Platelet Range:** 1.5 to 4.5 lakh/mm³ (150–450 x 10⁹/L). * **Bleeding Risk:** Spontaneous bleeding usually does not occur until platelets are **<20 x 10⁹/L** [1]. Surgical bleeding risk increases when platelets are **<50 x 10⁹/L**. * **Primary vs. Secondary Hemostasis:** Platelet defects (quantitative or qualitative) lead to **mucocutaneous bleeding** (petechiae, purpura, epistaxis), whereas clotting factor deficiencies (e.g., Hemophilia) lead to **deep tissue bleeding** (hemarthrosis, hematomas) [2].

Q: Which of the following conditions does NOT present with microcytic hypochromic anemia?

Aplastic anemia. The correct answer is **D. Aplastic anemia**. **1. Why Aplastic Anemia is the correct answer:** Aplastic anemia is characterized by **pancytopenia** resulting from bone marrow failure (hypocellular marrow). Since the defect lies in the stem cell population and not in hemoglobin synthesis, the red blood cells produced are typically **normocytic and normochromic** (normal size and color). In some cases, it may even present as macrocytic due to increased erythropoietin stress on remaining stem cells, but it is **never** a classic cause of microcytic hypochromic anemia. **2. Analysis of Incorrect Options:** Microcytic hypochromic anemia (MCV <80 fL, MCHC <32%) occurs when there is a defect in **hemoglobin synthesis**. This can be remembered by the mnemonic **TAILS**: * **T - Thalassemia (Option C):** Defect in globin chain synthesis. It presents with very low MCV and a high RBC count (Mentzer Index <13). * **A - Anemia of Chronic Disease (Option B):** Initially normocytic, but can become microcytic over time due to hepcidin-mediated iron sequestration [1]. * **I - Iron Deficiency Anemia (Option A):** The most common cause; due to lack of iron for the heme ring [1]. * **L - Lead Poisoning:** Inhibits enzymes (ALAD and Ferrochelatase) in the heme pathway. * **S - Sideroblastic Anemia:** Defect in protoporphyrin synthesis. **3. NEET-PG High-Yield Pearls:** * **Mentzer Index:** (MCV/RBC count). If ** 13**, suspect Iron Deficiency Anemia. * **Aplastic Anemia Gold Standard:** Bone marrow biopsy showing "dry tap" or "fatty replacement" (hypocellularity). * **Iron Studies:** In Anemia of Chronic Disease, **Ferritin is high/normal**, whereas in Iron Deficiency Anemia, **Ferritin is low** (the most sensitive initial test) [1].

Q: In a case of acute hemarthrosis in hemophilia, what is the recommended duration of treatment with factor VIII along with fresh frozen plasma?

Until joint effusion subsides. In acute hemarthrosis, Factor VIII replacement therapy (or Factor IX for Hemophilia B) should be initiated immediately. The treatment is not governed by a fixed number of days but is symptom-driven [1]. Therapy must continue until the joint effusion subsides, pain resolves, and the range of motion returns to baseline [1]. Stopping treatment prematurely while an effusion is still present increases the risk of re-bleeding and long-term synovial hypertrophy [1]. * Options A (3 days) and B (7 days): While many minor bleeds resolve within 3–7 days, these are arbitrary timeframes [1]. * Target Joint: Defined as a single joint in which 3 or more spontaneous bleeds have occurred within a 6-month period. * Factor Levels: For acute hemarthrosis, the goal is to raise Factor VIII levels to 40–60% of normal [1]. * Adjunctive Therapy: RICE (Rest, Ice, Compression, Elevation) is essential. However, aspirin and NSAIDs (except selective COX-2 inhibitors) must be avoided due to their effect on platelet function.

Q: What is the treatment of choice in hairy cell leukemia?

Cladribine. Explanation: **Hairy Cell Leukemia (HCL)** is a rare B-cell lymphoproliferative disorder characterized by pancytopenia, massive splenomegaly, and "hairy" cytoplasmic projections on peripheral smear. **Why Cladribine is the Correct Answer:** The treatment of choice for HCL is **Cladribine (2-Chlorodeoxyadenosine or 2-CdA)**. It is a purine nucleoside analog that is resistant to adenosine deaminase, leading to the accumulation of toxic nucleotides in B-cells. A single 7-day course of Cladribine induces complete remission in over 80-90% of patients, making it the gold standard first-line therapy. **Analysis of Incorrect Options:** * **Steroids (A):** Unlike in CLL or autoimmune hemolytic anemias, steroids have no significant role in treating the underlying malignancy in HCL and may increase the risk of opportunistic infections. * **Splenectomy (C):** Historically used to manage cytopenias and massive splenomegaly, it is now reserved for refractory cases or emergencies (e.g., splenic rupture). It is no longer the first-line treatment. * **Pentostatin (D):** Also a purine analog (adenosine deaminase inhibitor) and highly effective in HCL. However, **Cladribine** is preferred due to its shorter treatment duration and slightly better safety profile. **High-Yield Clinical Pearls for NEET-PG:** * **Marker of choice:** CD103 (most specific), CD11c, CD25, and Annexin A1. * **Genetic Mutation:** **BRAF V600E** mutation is present in nearly 100% of cases. * **Bone Marrow:** Often results in a **"Dry Tap"** due to increased reticulin fibrosis. * **Stain:** Tartrate-Resistant Acid Phosphatase (**TRAP**) positive. * **Clinical Hint:** Look for a patient with massive splenomegaly but **absent lymphadenopathy** (a classic HCL feature).

Q: Waldenstrom's macroglobulinemia is characterized by which of the following findings, except?

IgE secreting clone of plasma cells. **Explanation:** **Waldenström’s Macroglobulinemia (WM)** is a low-grade B-cell lymphoma characterized by the proliferation of **lymphoplasmacytic cells** that secrete a monoclonal **IgM** protein [1]. **1. Why Option A is the correct answer (The Exception):** WM is defined by the secretion of **IgM**, not IgE [1]. The presence of an IgE-secreting clone is extremely rare in plasma cell dyscrasias and is typically associated with IgE Multiple Myeloma, not WM. In WM, the "macroglobulin" refers specifically to IgM, which is the largest immunoglobulin pentamer. **2. Analysis of Incorrect Options (Findings present in WM):** * **Hyperviscosity symptoms (Option B):** Because IgM is a large pentameric molecule, high levels significantly increase blood viscosity. This leads to the classic triad of mucosal bleeding, visual disturbances (fundoscopic "sausage-link" veins), and neurological symptoms (headache, dizziness) [1]. * **Hepatosplenomegaly and Lymphadenopathy (Options C & D):** Unlike Multiple Myeloma, which is primarily confined to the bone marrow and causes lytic bone lesions, WM is a **lymphoproliferative disorder**. Therefore, infiltration of the reticuloendothelial system is common, leading to enlarged lymph nodes, liver, and spleen [1]. **Clinical Pearls for NEET-PG:** * **Hallmark Mutation:** Over 90% of patients possess the **MYD88 L265P** mutation. * **Bone Marrow:** Shows infiltration by **lymphoplasmacytic cells** (a mix of B-cells, plasma cells, and intermediate forms) [1]. * **Distinction from Multiple Myeloma:** WM does **not** typically cause lytic bone lesions or hypercalcemia. * **Treatment of Choice for Hyperviscosity:** Emergency **plasmapheresis** to rapidly lower IgM levels [1].

Question 1

Autoimmune hemolytic anemia is seen in which of the following conditions?

Accepted Answer

Chronic lymphocytic leukemia (CLL)

Answer

Chronic myeloid leukemia (CML)

Answer

Acute lymphoblastic leukemia (ALL)

Answer

Acute myeloid leukemia (AML)

Question 2

A patient has just been admitted to the hospital for observation. Based on the patient's laboratory results, what is the patient's primary problem? Hematocrit 45%, Hemoglobin 16 g/dL, Platelets 50 x 10^9/L.

Accepted Answer

Recurrent nosebleeds

Answer

Hemochromatosis

Answer

Deep vein thrombosis

Answer

Hepatic vein thrombosis

Question 3

Which of the following conditions does NOT present with microcytic hypochromic anemia?

Accepted Answer

Aplastic anemia

Answer

Iron deficiency anemia

Answer

Anemia of chronic disease

Answer

Thalassemia

Question 4

In a case of acute hemarthrosis in hemophilia, what is the recommended duration of treatment with factor VIII along with fresh frozen plasma?

Accepted Answer

Until joint effusion subsides

Answer

3 days

Answer

7 days

Answer

1 day

Question 5

A 25-year-old alcoholic man presents with easy fatigability and moderate pallor for the past six months. His Hb is 5.2 g/dL. What is the most appropriate initial treatment?

Accepted Answer

Pyridoxine supplementation

Answer

Iron supplementation

Answer

Ascorbic acid supplementation

Answer

Vitamin B12 supplementation

Question 6

Which one of the following laboratory tests differentiates leukemoid reaction from chronic myeloid leukemia?

Accepted Answer

Leukocyte alkaline phosphatase (LAP)

Answer

Leukocyte common antigen (LCA)

Answer

Myelo-peroxidase (MPO)

Answer

TRAP (tartrate resistant alkaline phosphatase)

Question 7

Which of the following is NOT true about aplastic anemia?

Accepted Answer

Splenomegaly

Answer

Reticulocytopenia

Answer

Thrombocytopenia

Answer

Neutropenia

Question 8

What is the treatment of choice in hairy cell leukemia?

Accepted Answer

Cladribine

Answer

Steroid

Answer

Splenectomy

Answer

Pentostatin

Question 9

Waldenstrom's macroglobulinemia is characterized by which of the following findings, except?

Accepted Answer

IgE secreting clone of plasma cells

Answer

Hyperviscosity symptoms

Answer

Hepatosplenomegaly

Answer

Lymphadenopathy

Question 10

Which is the most common preceding infection in bone marrow failure syndromes?

Accepted Answer

Hepatitis virus

Answer

Parvovirus B19

Answer

Epstein-Barr virus

Answer

Human Immunodeficiency Virus

Hematology — MCQs

Hematology — MCQs

On this page

Practice by Chapter

Want unlimited practice?